Immune‐Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non‐Small Cell Lung Cancer
Akamatsu, Hiroaki, Murakami, Eriko, Oyanagi, Jun, Shibaki, Ryota, Kaki, Takahiro, Takase, Eri, Tanaka, Masanori, Harutani, Yuhei, Yamagata, Nao, Okuda, Yuka, Furuta, Katsuyuki, Sugimoto, Takeya, Teraoka, Shunsuke, Hayata, Atsushi, Tokudome, Nahomi, Ozawa, Yuichi, Mori, Keita, Koh, Yasuhiro, Yamamoto, Nobuyuki
Published in The oncologist (Dayton, Ohio) (01.04.2020)
Published in The oncologist (Dayton, Ohio) (01.04.2020)
Get full text
Journal Article
MO3-10-3Sustained fever associated with immune checkpoint inhibitors may be a poor prognostic factor
Ueda, Hiroki, Murakami, Eriko, Okuda, Yuka, Takase, Eri, Kaki, Takahiro, Harutani, Yuhei, Yamagata, Nao, Furuta, Katsuyuki, Shimono, Chigusa, Yamamoto, Nobuyuki
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
Sustained fever associated with immune checkpoint inhibitors may be a poor prognostic factor
Ueda, Hiroki, Murakami, Eriko, Okuda, Yuka, Takase, Eri, Kaki, Takahiro, Harutani, Yuhei, Yamagata, Nao, Furuta, Katsuyuki, Shimono, Chigusa, Yamamoto, Nobuyuki
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer
Akamatsu, Hiroaki, Murakami, Eriko, Oyanagi, Jun, Shibaki, Ryota, Kaki, Takahiro, Takase, Eri, Tanaka, Masanori, Harutani, Yuhei, Yamagata, Nao, Okuda, Yuka, Furuta, Katsuyuki, Sugimoto, Takeya, Teraoka, Shunsuke, Hayata, Atsushi, Tokudome, Nahomi, Ozawa, Yuichi, Mori, Keita, Koh, Yasuhiro, Yamamoto, Nobuyuki
Published in The oncologist (Dayton, Ohio) (19.11.2019)
Get full text
Published in The oncologist (Dayton, Ohio) (19.11.2019)
Journal Article